113 related articles for article (PubMed ID: 36002192)
41. A pragmatic guide for management of adverse events associated with lorlatinib.
Liu G; Mazieres J; Stratmann J; Ou SI; Mok T; Grizzard M; Goto Y; Felip E; Solomon BJ; Bauer TM
Lung Cancer; 2024 May; 191():107535. PubMed ID: 38554546
[TBL] [Abstract][Full Text] [Related]
42. [Chinese Expert Consensus on Management of Special Adverse Effects
Associated with Lorlatinib].
Zhou Q; Lu S; Li Y; Jia F; Li G; Hong Z; Lu Y; Fan Y; Zhou J; Liu Z; Li J; Wu YL; ;
Zhongguo Fei Ai Za Zhi; 2022 Aug; 25(8):555-566. PubMed ID: 36002192
[TBL] [Abstract][Full Text] [Related]
43. Clinical Management of Adverse Events Associated with Lorlatinib.
Bauer TM; Felip E; Solomon BJ; Thurm H; Peltz G; Chioda MD; Shaw AT
Oncologist; 2019 Aug; 24(8):1103-1110. PubMed ID: 30890623
[TBL] [Abstract][Full Text] [Related]
44.
Shaw AT; Solomon BJ; Besse B; Bauer TM; Lin CC; Soo RA; Riely GJ; Ou SI; Clancy JS; Li S; Abbattista A; Thurm H; Satouchi M; Camidge DR; Kao S; Chiari R; Gadgeel SM; Felip E; Martini JF
J Clin Oncol; 2019 Jun; 37(16):1370-1379. PubMed ID: 30892989
[TBL] [Abstract][Full Text] [Related]
45. Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
Seto T; Hayashi H; Satouchi M; Goto Y; Niho S; Nogami N; Hida T; Takahashi T; Sakakibara-Konishi J; Morise M; Nagasawa T; Suzuki M; Ohkura M; Fukuhara K; Thurm H; Peltz G; Nishio M
Cancer Sci; 2020 Oct; 111(10):3726-3738. PubMed ID: 32681682
[TBL] [Abstract][Full Text] [Related]
46. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
Baldacci S; Besse B; Avrillon V; Mennecier B; Mazieres J; Dubray-Longeras P; Cortot AB; Descourt R; Doubre H; Quantin X; Duruisseaux M; Monnet I; Moro-Sibilot D; Cadranel J; Clément-Duchêne C; Cousin S; Ricordel C; Merle P; Otto J; Schneider S; Langlais A; Morin F; Westeel V; Girard N
Eur J Cancer; 2022 May; 166():51-59. PubMed ID: 35278825
[TBL] [Abstract][Full Text] [Related]
47. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
48. Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of China.
Lu S; Zhou Q; Liu X; Du Y; Fan Y; Cheng Y; Fang J; Lu Y; Huang C; Zhou J; Song Y; Wang K; Pan H; Yang N; Li J; Chen G; Chang J; Cui J; Liu Z; Bai C; Zhang H; Zhao H; Zhang K; Peltz G; Li H; Wu YL
J Thorac Oncol; 2022 Jun; 17(6):816-826. PubMed ID: 35307611
[TBL] [Abstract][Full Text] [Related]
49. Podcast on the Management of Adverse Events Associated with Lorlatinib.
Bauer TM; Bertino EM
Adv Ther; 2022 Apr; 39(4):1447-1456. PubMed ID: 35147918
[TBL] [Abstract][Full Text] [Related]
50. Cancer statistics in China and United States, 2022: profiles, trends, and determinants.
Xia C; Dong X; Li H; Cao M; Sun D; He S; Yang F; Yan X; Zhang S; Li N; Chen W
Chin Med J (Engl); 2022 Feb; 135(5):584-590. PubMed ID: 35143424
[TBL] [Abstract][Full Text] [Related]
51. Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System.
Sisi M; Fusaroli M; De Giglio A; Facchinetti F; Ardizzoni A; Raschi E; Gelsomino F
Target Oncol; 2022 Jan; 17(1):43-51. PubMed ID: 35025076
[TBL] [Abstract][Full Text] [Related]
52. [Recommendations from Experts in the Management of Adverse Reactions
to ALK Inhibitors (2021 Version)].
Wang K; Li J; Sun J; Li L; Zhang X; Zhang J; Yu M; Ye X; Zhang M; Zhang Y; Yao W; Huang M
Zhongguo Fei Ai Za Zhi; 2021 Dec; 24(12):815-828. PubMed ID: 34670356
[TBL] [Abstract][Full Text] [Related]
53. 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee.
Virani SS; Morris PB; Agarwala A; Ballantyne CM; Birtcher KK; Kris-Etherton PM; Ladden-Stirling AB; Miller M; Orringer CE; Stone NJ
J Am Coll Cardiol; 2021 Aug; 78(9):960-993. PubMed ID: 34332805
[No Abstract] [Full Text] [Related]
54. Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper.
Barata F; Aguiar C; Marques TR; Marques JB; Hespanhol V
Drug Saf; 2021 Aug; 44(8):825-834. PubMed ID: 34080177
[TBL] [Abstract][Full Text] [Related]
55. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Sung H; Ferlay J; Siegel RL; Laversanne M; Soerjomataram I; Jemal A; Bray F
CA Cancer J Clin; 2021 May; 71(3):209-249. PubMed ID: 33538338
[TBL] [Abstract][Full Text] [Related]
56. Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society.
Johkoh T; Lee KS; Nishino M; Travis WD; Ryu JH; Lee HY; Ryerson CJ; Franquet T; Bankier AA; Brown KK; Goo JM; Kauczor HU; Lynch DA; Nicholson AG; Richeldi L; Schaefer-Prokop CM; Verschakelen J; Raoof S; Rubin GD; Powell C; Inoue Y; Hatabu H
Chest; 2021 Mar; 159(3):1107-1125. PubMed ID: 33450293
[TBL] [Abstract][Full Text] [Related]
57. First-Line Lorlatinib or Crizotinib in Advanced
Shaw AT; Bauer TM; de Marinis F; Felip E; Goto Y; Liu G; Mazieres J; Kim DW; Mok T; Polli A; Thurm H; Calella AM; Peltz G; Solomon BJ;
N Engl J Med; 2020 Nov; 383(21):2018-2029. PubMed ID: 33207094
[TBL] [Abstract][Full Text] [Related]
58. Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non‑small cell lung cancer (Review).
Wang L; Wang W
Oncol Rep; 2021 Jan; 45(1):13-28. PubMed ID: 33200229
[TBL] [Abstract][Full Text] [Related]
59. Catalog of Lung Cancer Gene Mutations Among Chinese Patients.
Xue X; Asuquo I; Hong L; Gao J; Dong Z; Pang L; Jiang T; Meng M; Fan J; Wen J; Deng H; Zang X; Ma X; Guo R; Qin C; Meng Y; Ma H; Han J; Wang H; Xue Z; Zhao D; Lin D; Pan L
Front Oncol; 2020; 10():1251. PubMed ID: 32850378
[No Abstract] [Full Text] [Related]
60. Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners.
Reed M; Rosales AS; Chioda MD; Parker L; Devgan G; Kettle J
Adv Ther; 2020 Jun; 37(6):3019-3030. PubMed ID: 32399810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]